随着对抑制肿瘤信号通路、抑制肿瘤生长相关血管生成通路以及活化免疫系统发挥抗肿瘤作用等靶向抗肿瘤方法研究的不断进展，抗肿瘤抗体药物已经成为肿瘤领域不可或缺的治疗手段。临床批准的靶向抗肿瘤抗体药物主要包括分子靶向单克隆抗体（单抗）药物、抗体偶联药物、双特异性抗体药物以及靶向免疫检验点药物。近年来，肿瘤免疫治疗越发火热，上述具有免疫调节作用的抗体药物，或能增加肿瘤抗原性，或能促进肿瘤T细胞浸润，已经取得了巨大的临床收益；单抗药物的联用是未来的一大发展重点，无论是与肿瘤免疫疗法联用、与分子靶向抗体药物联用、与放化疗和小分子抑制剂药物甚至手术的联用，都将进一步提高抗体类药物在抗肿瘤治疗中的实用价值。

Many advances in the treatment of cancer have been driven by the development of targeted therapies that inhibit oncogenic signaling pathways and tumor-associated angiogenesis, as well as by the therapies that acti-vate immune system to unleash antitumor immunity. Many clinically approved therapies, including monoclonal anti-bodies，antibody-drug conjugates，bispecific antibodies and immune checkpoints, have become important strategies for cancer treatment. Recently, tumor immunotherapy is becoming more and more popular, and antibody medicines acquiring above mentioned immune-modulating effects, such as increasing tumor antigenicity or promoting intratu-moral T cell infiltration, had achieved great clinical benefits; monoclonal antibody medicine in combination with tu-mor immunotherapy, molecular targeted antibody medicine, chemotherapy or small molecular inhibitors and even surgery, will further enlarge the application value of antibody medicines in tumor therapies.

国家“重大新药创制”科技重大专项资助项目（No.2014ZX09201041-001）